Lv1
50 积分 2025-10-27 加入
The blockade of immune checkpoints in cancer immunotherapy
12天前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
12天前
已完结
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial
17天前
已完结
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
18天前
已完结
Gastric cancer
18天前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
1个月前
已完结
Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer
1个月前
已完结
Current status and future trends of the global burden of MASLD
1个月前
已完结
Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy
1个月前
已完结
Inhibition of CDGSH iron‑sulfur domain 2 exhibits tumor-suppressing effects on diffuse large B-cell lymphoma (DLBCL) by inducing ferroptosis through the regulation of the NRF2/SLC7A11/GPX4 pathway
1个月前
已完结
皖公网安备34019202002308
